Last Updated: November 16, 2026

List of Excipients in Branded Drug ZESTRIL

« Back to Dashboard


Zestril Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: October 27, 2026

Zestril is the branded lisinopril tablet, an angiotensin-converting enzyme inhibitor used for hypertension, heart failure, and acute myocardial infarction. Its compound and original formulation exclusivity have expired. Commercial opportunity now depends on differentiated dosage forms, pediatric delivery, adherence, supply reliability, and low-cost manufacturing rather than on the legacy Zestril brand.

The most practical excipient strategies are:

  1. A stable oral liquid or powder-for-reconstitution for pediatric and dysphagia markets.
  2. An orally disintegrating tablet or mini-tablet for adherence and swallowing problems.
  3. A moisture-controlled immediate-release tablet using robust, globally available excipients.
  4. A fixed-dose combination platform with hydrochlorothiazide, amlodipine, or other cardiovascular agents.
  5. A hospital and long-term-care product with unit-dose packaging and administration flexibility.

What is Zestril and which excipients does it contain?

Zestril contains lisinopril, the dihydrate form of the active pharmaceutical ingredient. It is administered orally as immediate-release tablets in 2.5 mg, 5 mg, 10 mg, 20 mg, and 40 mg strengths. FDA labeling identifies inactive ingredients including calcium phosphate, mannitol, magnesium stearate, starch, and iron oxide colorants in applicable strengths.[1]

Attribute Zestril profile
Active ingredient Lisinopril dihydrate
Drug class ACE inhibitor
Dosage form Immediate-release tablet
Strengths 2.5, 5, 10, 20, and 40 mg
Administration Oral, once daily in many indications
Food effect Food does not materially affect lisinopril absorption
Key formulation issue Low dose loading, hydrophilic API, tablet robustness, moisture and stability control
Original innovator Merck, later commercialized under the Zestril brand
Current market Generic lisinopril tablets and combination products

The Zestril tablet is a conventional immediate-release formulation. Its excipient system does not appear to provide a meaningful standalone commercial barrier because equivalent generic products use different but functionally conventional excipients.

What are the functional roles of Zestril excipients?

Calcium phosphate provides tablet mass and compression performance. Mannitol can improve mouthfeel and tablet bulk. Starch may act as a binder, disintegrant, or filler depending on grade and processing method. Magnesium stearate functions as a lubricant. Iron oxides provide color differentiation between strengths.

The excipient selection supports a low-cost, conventional tablet, but the system has limited differentiation. A new product would need to show a clinically relevant or commercially measurable advantage, such as faster disintegration, improved stability, easier administration, reduced tablet burden, or better pediatric acceptability.

What formulation characteristics matter for lisinopril excipient selection?

Lisinopril is a polar, water-soluble compound with relatively low oral bioavailability. Its product design is therefore less dependent on solubility enhancement than products containing poorly soluble APIs. Excipient strategy should focus on dose uniformity, chemical stability, manufacturability, and patient administration.

Dose uniformity at low strengths

The 2.5 mg and 5 mg strengths create a content-uniformity challenge because the active represents a small fraction of total tablet mass. Direct compression can be attractive for scale-up, but blend segregation and poor API distribution must be controlled.

Potential approaches include:

  • Geometric dilution or ordered blending.
  • Granulation to improve content uniformity.
  • Co-processed excipients for direct compression.
  • Low-shear blending with validated hold times.
  • Particle-size engineering or API premixing.
  • In-process weight and assay controls.

For a generic tablet, regulators will expect pharmaceutical equivalence and bioequivalence. An excipient change that affects disintegration or dissolution can create additional development risk even if the active dose is unchanged.

Moisture and chemical stability

Lisinopril products require stability assessment under ICH conditions, including accelerated humidity exposure. Excipient water activity, packaging permeability, and manufacturing humidity can affect degradation and tablet performance.

A commercial formulation should evaluate:

  • Low-moisture fillers.
  • Desiccant-compatible bottle packaging.
  • High-barrier blister films.
  • Nitrogen or controlled-humidity processing where justified.
  • Lubricant level and mixing time.
  • API-excipient compatibility under heat and humidity.
  • Degradation products during long-term storage.

Calcium phosphate, mannitol, and anhydrous or low-moisture excipient grades may support stability, but the optimal combination must be demonstrated through forced-degradation and stability studies.

Disintegration and dissolution

Lisinopril tablets should disintegrate rapidly enough to meet immediate-release performance expectations. Crospovidone, croscarmellose sodium, sodium starch glycolate, or low-substituted hydroxypropyl cellulose could be evaluated as alternatives to conventional starch systems.

A faster-disintegrating formulation may support an orally disintegrating tablet, but faster disintegration alone is unlikely to create a strong patent position. A defensible product would need a defined composition range, process control, performance data, and a commercial reason for the change.

What excipient strategies create the strongest commercial opportunities?

Oral liquid and powder-for-reconstitution products

A lisinopril oral liquid could address pediatric patients, older adults, patients with dysphagia, and individuals receiving medication through feeding tubes. The main technical challenge is maintaining chemical and microbiological stability at a clinically useful concentration.

Potential excipient classes include:

  • Purified water for aqueous systems.
  • Buffers to control pH.
  • Sweeteners such as sucralose or sucrose.
  • Polyols such as sorbitol or glycerol.
  • Suspending agents if a suspension is used.
  • Preservatives where justified.
  • Flavor systems for pediatric acceptability.
  • Chelating agents or antioxidants if compatible with the formulation.

A powder-for-reconstitution may reduce microbial and chemical stability risks during distribution. It can also reduce shipping weight and improve shelf life before reconstitution. The commercial weakness is operational complexity: pharmacies and caregivers must reconstitute, label, store, and measure the product correctly.

A ready-to-use liquid has a broader use case but faces higher packaging, preservative, microbial, and stability requirements.

Orally disintegrating tablets

An ODT could target patients who have difficulty swallowing conventional tablets. Mannitol, microcrystalline cellulose, crospovidone, croscarmellose sodium, and specialized flavor systems are common development options.

The main risks are:

  • Bitter or metallic taste.
  • Low drug loading at the 2.5 mg and 5 mg strengths.
  • Friability during packaging and transport.
  • Moisture sensitivity.
  • Need for specialized blister packaging.
  • Limited willingness to pay in a mature generic category.

Taste masking is a central issue. Lisinopril is not generally marketed as a flavored product, and palatability data would be important for pediatric or geriatric positioning.

Mini-tablets and sprinkle formulations

Mini-tablets can provide flexible dosing and support administration to children or patients with swallowing difficulties. A sprinkle capsule or sachet could allow administration with soft food, but taste, dose uniformity, and stability after opening must be established.

This strategy may be more commercially practical than an ODT where flexible dosing is more important than rapid oral disintegration.

Fixed-dose combination products

Combination products may offer greater commercial value than a single-agent excipient reformulation. Existing cardiovascular combinations include lisinopril with hydrochlorothiazide. Other combinations could be evaluated where clinically and regulatorily appropriate.

The formulation must control:

  • Chemical compatibility between APIs.
  • Separate dissolution behavior.
  • Dose ratio and titration limitations.
  • Tablet size.
  • Stability of each active.
  • Bioequivalence against the relevant reference products.

A fixed-dose combination can generate a more defensible formulation patent if it includes a specific composition, release profile, or manufacturing process. It still faces substantial prior-art and obviousness risk because ACE inhibitor combinations are well established.

What patents protect Zestril and lisinopril formulations?

The original lisinopril compound patent estate has expired. The core lisinopril patent commonly associated with the original product is U.S. Patent No. 4,374,829, assigned to Merck.[2] The historical compound protection no longer blocks generic lisinopril development.

IP category Current commercial relevance
Lisinopril compound patent Expired
Original Zestril tablet patents Expired or no longer commercially blocking
Method-of-use patents Any remaining rights must be reviewed claim by claim; core uses are long established
Formulation patents Possible for new liquids, ODTs, combinations, packaging, or manufacturing processes
Excipient-only claims Generally weak unless tied to a defined performance advantage
Trade secrets Blend order, granulation, coating, packaging, and process controls may remain useful
Regulatory exclusivity No meaningful new-drug exclusivity for conventional generic lisinopril

A new formulation patent would need more than a list of familiar excipients. Stronger claim concepts could include:

  • A narrow pH and preservative system for a stable liquid.
  • A specific low-moisture tablet composition.
  • A defined ODT disintegration and friability profile.
  • A reconstitution system with an extended in-use period.
  • A combination product with demonstrated stability and bioequivalence.
  • A manufacturing sequence that solves content-uniformity or degradation problems.

The patentability risk is high because lisinopril tablets, ACE inhibitor liquids, ODT technologies, and cardiovascular combinations are extensively documented. Unexpected stability, bioavailability, palatability, or adherence data would improve the position.

What is the Orange Book status of Zestril?

The FDA Orange Book records approved prescription drug products and patent or exclusivity information submitted for listed products. Zestril is a legacy lisinopril product, while multiple generic lisinopril products have been approved through abbreviated new drug applications.[3]

For a conventional generic applicant, the relevant pathway is generally an ANDA with a Paragraph III or Paragraph IV certification depending on the status of any listed patents. The original lisinopril blocking patents have expired, so the central regulatory issue is pharmaceutical equivalence, bioequivalence, labeling, manufacturing quality, and supply reliability rather than a live compound patent barrier.

A new liquid, ODT, or combination product may require a different regulatory strategy. Depending on the reference product and formulation, the sponsor may use an ANDA, a 505(b)(2) application, or another FDA pathway. A formulation that differs materially from the approved reference product may not fit a straightforward ANDA strategy.

When did Zestril lose exclusivity?

Zestril lost meaningful market exclusivity after expiration of the original lisinopril patent protection and subsequent generic entry. The product is now exposed to broad generic competition. Any remaining exclusivity or listing issue must be evaluated against the specific NDA, strength, dosage form, and Orange Book record.

The practical consequence is clear: a new entrant cannot rely on Zestril brand exclusivity. It must compete through cost, supply, dosage-form differentiation, combination therapy, packaging, or distribution.

Which companies are challenging or competing with Zestril?

The competitive set includes generic lisinopril manufacturers and suppliers of combination products. Major generic companies have historically marketed lisinopril tablets, including Teva, Sandoz, Lupin, Mylan, and other ANDA holders, depending on product availability and market period.

Competition is primarily based on:

  • Contract manufacturing cost.
  • API sourcing.
  • FDA compliance history.
  • Wholesaler access.
  • Shortage performance.
  • Bottle and blister packaging.
  • Strength portfolio.
  • Combination-product availability.

There is no meaningful biosimilar risk because lisinopril is a chemically synthesized small molecule, not a biologic. The relevant threat is generic substitution and therapeutic competition from other antihypertensive classes.

What generic entry risks exist for a new lisinopril product?

A new lisinopril product faces five principal risks.

Risk Commercial effect
Low generic pricing Limits return on conventional tablets
Weak differentiation Makes pharmacy substitution likely
Bioequivalence failure Delays approval and raises development cost
Stability problems Creates recalls, short dating, or excess packaging cost
Limited market access Reduces volume despite technical superiority

A conventional tablet with a different excipient profile is unlikely to secure a durable premium. The stronger opportunity is a product that solves an operational problem for a defined customer group, such as pediatric dosing, feeding-tube administration, long-term-care medication management, or shortage-prone hospital supply.

What manufacturing and IP barriers affect lisinopril excipient opportunities?

Manufacturing barriers are moderate for standard tablets and higher for liquids, ODTs, and combinations.

For tablets, the key controls are blend uniformity, compression force, capping, friability, dissolution, and moisture exposure. For liquids, the key controls are pH, preservative effectiveness, microbial limits, viscosity, sedimentation, dose delivery, and in-use stability. For ODTs, the critical attributes include mechanical strength, disintegration time, packaging integrity, and palatability.

Geographic coverage is less likely to come from legacy Zestril patents because the original estate has expired. Protection may instead come from new formulation patents filed in the United States, Europe, Japan, China, and other major markets. Trade-secret protection is most relevant to manufacturing parameters and excipient processing.

How strong is the patent estate for a new Zestril excipient formulation?

The patent estate is weak for a routine reformulation and potentially moderate for a technically differentiated product supported by comparative data.

Product concept Patent strength Commercial potential
Same immediate-release tablet with new filler Low Low
Lower-cost direct-compression tablet Low to moderate Moderate at high volume
Stable ready-to-use oral liquid Moderate Moderate to high in selected populations
Powder-for-reconstitution Moderate Moderate
ODT with taste masking Moderate Moderate
Pediatric mini-tablet or sprinkle product Moderate Moderate
Fixed-dose combination Moderate Moderate to high, subject to competition
Novel controlled-release lisinopril Uncertain and technically difficult Limited unless clinical benefit is shown

What licensing deals and partnerships are commercially relevant?

The most relevant opportunities are development and supply partnerships rather than licenses to the Zestril brand. Potential counterparties include:

  • Generic pharmaceutical manufacturers.
  • Pediatric formulation specialists.
  • Contract development and manufacturing organizations.
  • Hospital and long-term-care distributors.
  • Excipients suppliers with co-processed direct-compression systems.
  • Packaging companies offering high-barrier unit-dose systems.

A licensing transaction would be more attractive if it includes an issued formulation patent, FDA approval, validated shelf life, and an established distribution channel. An unapproved excipient concept without clinical or regulatory data would command limited value in a mature generic market.

Key Takeaways

  • Zestril is an established lisinopril immediate-release tablet with expired core exclusivity.
  • Conventional excipient substitution offers limited commercial and patent value.
  • The best opportunities are oral liquids, ODTs, mini-tablets, sprinkle products, and fixed-dose combinations.
  • Low-dose content uniformity, moisture control, dissolution, taste, and packaging are the principal technical issues.
  • A new formulation may qualify for patent protection only if it has a defined composition or process linked to an unexpected or commercially important performance result.
  • Generic competition and low pricing make supply reliability and customer-specific delivery formats more important than brand extension.
  • Biosimilar risk is irrelevant; generic substitution is the central competitive threat.
  • The most credible commercial model is a differentiated lisinopril product supported by FDA approval, strong stability data, and a focused distribution strategy.

FAQs About Zestril Excipient Strategy

Can a company patent a new excipient combination for lisinopril?

Yes, but a generic excipient list is unlikely to be sufficient. The formulation should have a narrow, non-obvious composition or process and evidence of improved stability, dissolution, palatability, administration, or manufacturing performance.

Is lisinopril suitable for an oral liquid?

Yes. An oral liquid could address pediatric and dysphagia markets, but the formulation must control pH, microbial growth, chemical stability, dose measurement, and in-use shelf life.

Does Zestril still have compound patent protection?

No meaningful compound exclusivity remains for the original lisinopril product. The relevant commercial barriers are generic competition, regulatory compliance, manufacturing capability, and any later formulation-specific rights.

Is an ODT version of lisinopril commercially attractive?

It can be attractive in selected adherence and swallowing-disorder populations. Its value depends on taste masking, fast disintegration, packaging stability, and evidence that customers will pay more than for generic tablets.

What is the most defensible commercial opportunity around Zestril?

A stable, easy-to-administer pediatric or dysphagia formulation, supported by a focused FDA strategy and differentiated packaging, is more defensible than another conventional lisinopril tablet.

References

  1. U.S. Food and Drug Administration. (n.d.). Zestril (lisinopril) tablets: Prescribing information. DailyMed.
  2. United States Patent and Trademark Office. (1983). U.S. Patent No. 4,374,829: 1-[(1-carboxy-3-phenyl-propyl)-L-lysyl]-L-proline.
  3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.